Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

• Váldodahkkit: Alistair Ring (Dahkki), Meghan Karuturi (Dahkki), Emily Nash Smyth (Dahkki), Tasneem Lokhandwala (Dahkki), Kristin M. Sheffield (Dahkki), Joanne Willey (Dahkki), Orsolya Lunacsek (Dahkki), Francisco Sapunar (Dahkki), Zhanglin Lin Cui (Dahkki), Anna D. Coutinho (Dahkki), Sarah Rybowski (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcome...